Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS

(MedPage Today) -- CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the current standard of care...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news